Choose DARZALEX FASPRO® + VRd to treat newly diagnosed,   transplant-eligible multiple myeloma patients

Image of healthcare professionals rolling out Darzalex efficacy results

In the treatment of newly diagnosed, transplant-ineligible multiple myeloma1:

ADVANCE THE FRONTLINE MOMENTUM WITH DARZALEX® + Rd

Help your patients live longer than Rd alone with DRd, an established frontline treatment proven to significantly extend overall survival1

Review OS results
Image of Ruemu E. Birhiray, MD

HEAR FROM MULTIPLE MYELOMA EXPERTS

Watch KOL expert series videos on treating patients with newly diagnosed, transplant-ineligible multiple myeloma

View videos

After 56 months: 32% reduction in the risk of death with DRd vs Rd alone in the MAIA trial (HR=0.68; 95% CI: 0.53, 0.86; P=0.0013; mOS not reached in either arm).*1

Continuous treatment icon

Keep patients on a proven path with frontline DARZALEX® + Rd for newly diagnosed, transplant-ineligible multiple myeloma1

Explore continuing treatment
Checklist icon

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for regimens containing daratumumab (DARZALEX®)

Discover NCCN recommendations
Syringe icon

Administration options include ~3 to 5 minute subcutaneous DARZALEX FASPRO® and intravenous DARZALEX®†1,2

Learn about sub-Q administration

*Median follow-up was 56.6 months in the DRd group (IQR: 53.0-60.1 months) and 55.9 months in the Rd group (IQR: 52.5-59.4 months).3

†DARZALEX FASPRO® is administered by subcutaneous injection over approximately 3 to 5 minutes. In contrast, DARZALEX® is administered by intravenous infusion over approximately 7, 4, and 3 hours for first, second, and subsequent infusions, respectively.1,2 View IV administration

‡Cytogenetic risk was based on fluorescence in situ hybridization (FISH) or karyotype analysis. High-risk cytogenetics were defined as having at least one of the following abnormalities: t[4;14], t[14;16], del[17p], t[14;20], gain[1q21], amp[1q21].4

Advancing frontline knowledge: KOL expert series

Watch multiple myeloma experts provide their perspectives on treating newly diagnosed, transplant-ineligible multiple myeloma

Patient considerations when determining frontline treatment

Dr. Kenneth Shain, Director of the Myeloma Working Group at Moffitt Cancer Center (Tampa, Florida), discusses a typical patient seen in his practice and how he reviews safety and efficacy data along with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) when choosing a frontline treatment option.

MAIA study on frontline treatment with DARZALEX® + Rd vs Rd alone, including primary results, and post hoc analysis in frail patients

Dr. Ruemu Birhiray, the founder of Indy Hematology Review, explores safety and efficacy data of the MAIA trial, including a post hoc analysis in frail patients.

MAIA study of patients on frontline triplet DARZALEX® + Rd vs Rd alone, along with high-risk subgroup analysis

Dr. Kenneth Shain reviews the efficacy and safety of DRd vs Rd from the MAIA trial, including a subgroup analysis in patients with a high-risk cytogenetic profile.

CI=confidence interval; DRd=DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); DVRd=DARZALEX® (D) + bortezomib (V) + lenalidomide (R) + dexamethasone (d); HR=hazard ratio; IQR=interquartile range; IV=intravenous; KOL=key opinion leader; MM=multiple myeloma; mOS=median overall survival; NCCN=National Comprehensive Cancer Network; OS=overall survival; Rd=lenalidomide (R) + dexamethasone (d); sub-Q=subcutaneous; VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

References:

  1. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582-1596.
  4. Moreau P, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 MAIA study. Poster presented at: 64th American Society of Hematology (ASH) Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA.